Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19097593 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | Final Rejection | Avidity Biosciences, Inc. |
| 18046860 | ACTIVATABLE POLYPEPTIDE COMPLEX | Non-Final OA | Amgen, Inc. |
| 18345670 | METHODS FOR STIMULATING PROLIFERATION OR DIFFERENTIATION OF AN IMMUNE CELL WITH A MULTI-CHAIN CHIMERIC POLYPEPTIDE | Non-Final OA | ImmunityBio, Inc. |
| 18347541 | METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES | Non-Final OA | Northwestern University |
| 18494630 | Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody | Non-Final OA | FRESENIUS KABI DEUTSCHLAND GMBH |
| 18199007 | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18695464 | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | Final Rejection | Vellera Therapeutics, Inc. |
| 18695502 | METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS | Final Rejection | Aslan Pharmaceuticals Pte Ltd |
| 18273683 | TREATMENT OF CHRONIC PRURIGO | Non-Final OA | Celldex Therapeutics, Inc. |
| 18028240 | TIGHT JUNCTION (ZONULAE OCCLUDENTES) PROTEIN FOR USE IN TREATING OR PREVENTING EPILEPSY | Non-Final OA | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY |
| 18336769 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | Non-Final OA | Bayer Pharma Aktiengesellschaft |
| 18299566 | METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2 | Non-Final OA | Paradigm Immunoterapeutics, Inc. |
| 18146149 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 16795450 | DUAL PDGF/VEGF ANTAGONISTS | Final Rejection | KODIAK SCIENCES INC. |
| 17979323 | Multifunctional Heteromultimeric Constructs | Non-Final OA | Université de Reims Champagne Ardenne URCA |
| 17253958 | COMPLEMENT ANAPHYLATOXIN BINDERS AND THEIR USE IN TREATMENT OF A SUBJECT HAVING AN OCULAR WOUND AND/OR FIBROSIS | Final Rejection | CHARITE - UNIVERSITATSMEDIZIN BERLIN |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy